A new approach to the debilitating bone loss disease osteoporosis could be on the horizon thanks to research by Andreas Zimmer and Meliha Karsak from the Bonn-based Life & Brain Center in Germany and collaborators in Israel, the UK, and the USA. The researchers have discovered a regulatory mechanism involved in bone loss linked to a chemical receptor in our bodies with a previously unknown function, which could lead to a new treatment. The team has now developed a new synthetic compound, HU-308, which activates CB2 and slows the development of osteoporosis in mice. This compound forms the basis for a cannabinoid-based, anti-osteoporotic type drug which has also been found to be free of any psychoactive side effects.
Toking up on osteoporosis science